Cargando…

Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib

BACKGROUND: It is not clear whether tumor marker responses can predict survival during sorafenib treatment in hepatocellular carcinoma (HCC). We investigated whether the α-fetoprotein (AFP) response is associated with survival in patients with advanced HCC treated with sorafenib. METHODS: We retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sangheun, Kim, Beom Kyung, Kim, Seung Up, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Han, Kwang-Hyub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918283/
https://www.ncbi.nlm.nih.gov/pubmed/27508193
http://dx.doi.org/10.2147/JHC.S79353
_version_ 1782439095470915584
author Lee, Sangheun
Kim, Beom Kyung
Kim, Seung Up
Park, Jun Yong
Kim, Do Young
Ahn, Sang Hoon
Han, Kwang-Hyub
author_facet Lee, Sangheun
Kim, Beom Kyung
Kim, Seung Up
Park, Jun Yong
Kim, Do Young
Ahn, Sang Hoon
Han, Kwang-Hyub
author_sort Lee, Sangheun
collection PubMed
description BACKGROUND: It is not clear whether tumor marker responses can predict survival during sorafenib treatment in hepatocellular carcinoma (HCC). We investigated whether the α-fetoprotein (AFP) response is associated with survival in patients with advanced HCC treated with sorafenib. METHODS: We retrospectively reviewed the records of 126 patients with advanced HCC treated with sorafenib between 2007 and 2012. An AFP response was defined as >20% decrease from baseline. At 6–8 weeks after commencing sorafenib, AFP and radiological responses were assessed by modified Response Evaluation Criteria in Solid Tumors. RESULTS: The median overall survival (OS) and progression-free survival (PFS) were 6.2 and 3.5 months, respectively. Of the study population, a partial response (PR) was identified in 5 patients (4.0%), stable disease (SD) in 65 patients (51.6%), and progressive disease (PD) in 57 patients (44.4%), respectively. AFP non-response was an independent prognostic factor for poor OS (median 10.9 months for AFP response vs 5.2 months for AFP non-response), together with Child-Pugh B, tumor diameter ≥10 cm, and portal vein invasion (all P<0.05), and PFS (median 5.3 months for AFP response vs 2.9 months for AFP non-response), together with tumor diameter ≥10 cm and portal vein invasion (all P<0.05). SD or PR was more frequently found in AFP responders than in non-responders (72.1% vs 47.0%, respectively; P=0.007). In a sub-group with SD, OS (median 12.7 vs 5.8 months, respectively) and PFS (median 9.1 vs 3.7 months, respectively) were significantly longer in AFP responders than in non-responders (all P<0.05). CONCLUSION: Early AFP response may be useful for predicting survival in patients with advanced HCC treated with sorafenib.
format Online
Article
Text
id pubmed-4918283
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49182832016-08-09 Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib Lee, Sangheun Kim, Beom Kyung Kim, Seung Up Park, Jun Yong Kim, Do Young Ahn, Sang Hoon Han, Kwang-Hyub J Hepatocell Carcinoma Original Research BACKGROUND: It is not clear whether tumor marker responses can predict survival during sorafenib treatment in hepatocellular carcinoma (HCC). We investigated whether the α-fetoprotein (AFP) response is associated with survival in patients with advanced HCC treated with sorafenib. METHODS: We retrospectively reviewed the records of 126 patients with advanced HCC treated with sorafenib between 2007 and 2012. An AFP response was defined as >20% decrease from baseline. At 6–8 weeks after commencing sorafenib, AFP and radiological responses were assessed by modified Response Evaluation Criteria in Solid Tumors. RESULTS: The median overall survival (OS) and progression-free survival (PFS) were 6.2 and 3.5 months, respectively. Of the study population, a partial response (PR) was identified in 5 patients (4.0%), stable disease (SD) in 65 patients (51.6%), and progressive disease (PD) in 57 patients (44.4%), respectively. AFP non-response was an independent prognostic factor for poor OS (median 10.9 months for AFP response vs 5.2 months for AFP non-response), together with Child-Pugh B, tumor diameter ≥10 cm, and portal vein invasion (all P<0.05), and PFS (median 5.3 months for AFP response vs 2.9 months for AFP non-response), together with tumor diameter ≥10 cm and portal vein invasion (all P<0.05). SD or PR was more frequently found in AFP responders than in non-responders (72.1% vs 47.0%, respectively; P=0.007). In a sub-group with SD, OS (median 12.7 vs 5.8 months, respectively) and PFS (median 9.1 vs 3.7 months, respectively) were significantly longer in AFP responders than in non-responders (all P<0.05). CONCLUSION: Early AFP response may be useful for predicting survival in patients with advanced HCC treated with sorafenib. Dove Medical Press 2015-04-28 /pmc/articles/PMC4918283/ /pubmed/27508193 http://dx.doi.org/10.2147/JHC.S79353 Text en © 2015 Lee et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Lee, Sangheun
Kim, Beom Kyung
Kim, Seung Up
Park, Jun Yong
Kim, Do Young
Ahn, Sang Hoon
Han, Kwang-Hyub
Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
title Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
title_full Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
title_fullStr Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
title_full_unstemmed Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
title_short Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
title_sort early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918283/
https://www.ncbi.nlm.nih.gov/pubmed/27508193
http://dx.doi.org/10.2147/JHC.S79353
work_keys_str_mv AT leesangheun earlyafetoproteinresponsepredictssurvivalinpatientswithadvancedhepatocellularcarcinomatreatedwithsorafenib
AT kimbeomkyung earlyafetoproteinresponsepredictssurvivalinpatientswithadvancedhepatocellularcarcinomatreatedwithsorafenib
AT kimseungup earlyafetoproteinresponsepredictssurvivalinpatientswithadvancedhepatocellularcarcinomatreatedwithsorafenib
AT parkjunyong earlyafetoproteinresponsepredictssurvivalinpatientswithadvancedhepatocellularcarcinomatreatedwithsorafenib
AT kimdoyoung earlyafetoproteinresponsepredictssurvivalinpatientswithadvancedhepatocellularcarcinomatreatedwithsorafenib
AT ahnsanghoon earlyafetoproteinresponsepredictssurvivalinpatientswithadvancedhepatocellularcarcinomatreatedwithsorafenib
AT hankwanghyub earlyafetoproteinresponsepredictssurvivalinpatientswithadvancedhepatocellularcarcinomatreatedwithsorafenib